TY - JOUR
T1 - Evaluation of the Short-Term Treatment of Insomnia in Out-Patients with 15 Milligrams of Quazepam
AU - Mendels, Joseph
AU - Stern, S.
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1983/5
Y1 - 1983/5
N2 - The short-term safety and hypnotic efficacy of 15 mg of quazepam was compared with that of placebo in a double-blind study in sixty out-patients with insomnia. All patients received placebo for 3 consecutive nights to establish a baseline; for the next 5 nights thirty patients received quazepam and thirty received placebo. The results indicated that quazepam was significantly more effective than placebo in terms of quantity and quality of sleep and that quazepam was effective on the first night. Despite having a marked hypnotic effect, quazepam was not different from placebo in terms of hang-over effects (i.e., ease in awakening and alertness) the following morning. Treatment-related adverse experiences were reported by ten patients who received quazepam and by five who received only placebo. The most frequently reported adverse experience was daytime somnolence. This study demonstrates that quazepam, in a 15 mg dose, is an effective, rapidly acting, oral hypnotic agent with a low incidence of adverse effects.
AB - The short-term safety and hypnotic efficacy of 15 mg of quazepam was compared with that of placebo in a double-blind study in sixty out-patients with insomnia. All patients received placebo for 3 consecutive nights to establish a baseline; for the next 5 nights thirty patients received quazepam and thirty received placebo. The results indicated that quazepam was significantly more effective than placebo in terms of quantity and quality of sleep and that quazepam was effective on the first night. Despite having a marked hypnotic effect, quazepam was not different from placebo in terms of hang-over effects (i.e., ease in awakening and alertness) the following morning. Treatment-related adverse experiences were reported by ten patients who received quazepam and by five who received only placebo. The most frequently reported adverse experience was daytime somnolence. This study demonstrates that quazepam, in a 15 mg dose, is an effective, rapidly acting, oral hypnotic agent with a low incidence of adverse effects.
UR - http://www.scopus.com/inward/record.url?scp=0020519252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020519252&partnerID=8YFLogxK
U2 - 10.1177/030006058301100305
DO - 10.1177/030006058301100305
M3 - Article
C2 - 6347747
AN - SCOPUS:0020519252
VL - 11
SP - 155
EP - 161
JO - Journal of International Medical Research
JF - Journal of International Medical Research
SN - 0300-0605
IS - 3
ER -